GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
50 hedge funds and large institutions have $65.2M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
28% more funds holding
Funds holding: 39 → 50 (+11)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
77% less capital invested
Capital invested by funds: $280M → $65.2M (-$215M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.61M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.73M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
+$803K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$773K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCMH
Oxbow Capital Management (HK)
Hong Kong
|
-$4.64M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$3.85M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.81M |
| 4 |
Jane Street
New York
|
-$686K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$604K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PVI
51
Pura Vida Investments
New York
| – | -$3.85M | -400,000 | Closed |
|
|
52
Jane Street
New York
| – | -$686K | -71,200 | Closed |
|
|
53
Citadel Advisors
Miami,
Florida
| – | -$604K | -62,690 | Closed |
|
|
KC
54
Kepos Capital
New York
| – | -$568K | -59,000 | Closed |
|
|
ECM
55
ExodusPoint Capital Management
New York
| – | -$407K | -42,231 | Closed |
|
|
WAM
56
Weiss Asset Management
Boston,
Massachusetts
| – | -$275K | -28,565 | Closed |
|
57
Goldman Sachs
New York
| – | -$258K | -26,807 | Closed |
|
58
Balyasny Asset Management
Chicago,
Illinois
| – | -$142K | -14,715 | Closed |
|
|
SM
59
Sciencast Management
Princeton,
New Jersey
| – | -$137K | -13,348 | Closed |
|
|
YIH
60
Y-Intercept (HK)
Hong Kong
| – | -$123K | -12,789 | Closed |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$13.8K | -1,995 | -96% |
|
|
OCM
62
Ovata Capital Management
Hong Kong
| – | -$11K | -1,100 | Closed |
|
GRNA Hedge Fund Activity: Q2 2022 in Review
50 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q2 2022, worth a combined $65.2M — down 77% from $280M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new GRNA positions and 12 closed out — a net gain of 12 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $4.61M. The largest seller was Oxbow Capital Management (HK), exiting entirely with an estimated $4.64M sold.
- 50 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $65.2M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q2 2022, down 77% quarter-over-quarter.
- 24 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q2 2022 and 12 closed out, a net change of +12 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q2 2022 was BlackRock, an estimated $4.61M added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q2 2022 was Oxbow Capital Management (HK), an estimated $4.64M sold.
Based on aggregated 13F filings for Q2 2022.